Kiniksa Pharmaceuticals International, plc (KNSA)

NMS – Real Time Price. Currency in USD

59.48

+1.11 (1.90%)

At close: May 12, 2026, 4:00 PM EDT

59.99

+0.51 (0.86%)

Pre-market: May 13, 2026, 5:21 AM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

678M

423M

270M

220M

Cost of goods sold

-307M

-190M

-91M

-51M

Gross Profit

370M

234M

179M

169M

Operating expenses (excl. COGS)

-293M

-279M

-204M

-159M

Operating Income

77M

-46M

-25M

10M

Non-operating income, total

12M

Pretax income

89M

-36M

-17M

11M

Equity in earnings

Taxes

-30M

-7M

31M

172M

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

59M

-43M

14M

183M

Kiniksa Pharmaceuticals International, plc (KNSA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kiniksa Pharmaceuticals International, plc (KNSA)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Kiniksa Pharmaceuticals International, plc (KNSA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kiniksa Pharmaceuticals International, plc (KNSA)

Income Statement (Annual)

Income Statement (Annual)